A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses

  1. Tamas Bartfai*,,,
  2. M. Margarita Behrens*,,
  3. Svetlana Gaidarova*,,
  4. Janell Pemberton*,,
  5. Alexander Shivanyuk§,, and
  6. Julius Rebek, Jr,§,
  1. Departments of *Neuropharmacology and §Chemistry, The Harold L. Dorris Neurological Research Center, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037
  1. Contributed by Julius Rebek, Jr., May 7, 2003

Abstract

Toll-like receptors (TLRs) and the type I IL-1 receptor (IL-1RI) are key components of the innate immune system activated by microbial infections and inflammation. The signaling cascade from agonist-occupied TLRs and IL-1Rs involves recruitment of the small cytosolic adapter protein MyD88 that binds to IL-1RI via homotypic interactions mediated by Toll/IL-1R/resistance (TIR) domains. Dominant negative forms and null mutations of MyD88 have recently been shown to preclude bacterial product or IL-1-mediated activation of NF-κB pathways, demonstrating that MyD88 is an essential component of the Toll receptor signaling. Here, we report the synthesis and pharmacological effects of a low molecular weight MyD88 mimic, hydrocinnamoyl-l-valyl pyrrolidine (compound 4a), modeled on a tripeptide sequence of the BB-loop [(F/Y)-(V/L/I)-(P/G)] of the TIR domain. Results are presented showing that compound 4a interferes with the interactions between mouse MyD88 and IL-1RI at the TIR domains. Compound 4a inhibited IL-1β-induced phosphorylation of the mitogen-activated protein kinase p38 in EL4 thymoma cells and in freshly isolated murine lymphocytes in a concentration-dependent manner. In vivo, compound 4a produced a significant attenuation of the IL-1β-induced fever response (200 mg/kg, i.p.). Inhibition of the TIR domain-mediated MyD88/IL1-RI interaction by a low molecular weight, cell-penetrating TIR domain mimic suggests an intracellular site for antiinflammatory drug action.

Footnotes

  • To whom correspondence should be addressed. E-mail: tbartfai{at}scripps.edu or jrebek{at}scripps.edu.

  • Abbreviations: TLR, Toll-like receptor; IL-1RI, type I IL-1 receptor; IL-1RAcP, IL-1R accessory protein; TIR, Toll/IL-1R/resistance; LPS, lipopolysaccharide; DCM, dichloromethane; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; JNK, c-Jun aminoterminal kinase.

« Previous | Next Article »Table of Contents